Insilico Medicine has announced the beginning of a partnership with Ageing Research at King’s (ARK), a new world-class multi-disciplinary center for ageing research formed at King's College London.
The collaboration will be dedicated to enhancing multidisciplinary research collaborations across King’s College London and King’s Health Partners to better understand the mechanisms of ageing and improving health-span, with a goal to employ a set of AI-based methods and to explore patterns that have significant potential to impact healthy ageing, age-related diseases and targeted therapeutics.
The newly developed ‘ARK’ will develop a programme of events to facilitate networking in AI research across King’s and to foster research supported by UK Research and Innovation, charities and industrial partners both in the UK and globally.
The applications of modern artificial intelligence algorithms within the field of aging research is set to offer “tremendous opportunities”, according to Alex Zhavoronkov, founder, and CEO of Insilico Medicine.
He continued, “Insilico Medicine is one of the first AI companies to combine the expertise in artificial intelligence applied to the cutting-edge medicinal chemistry and target identification, and I am certain that our set of software tools, deep domain expertise in target identification and medicinal chemistry, and focus on aging and age-related diseases will contribute to the ARK’s initiative and research.”